The U.S. Food and Drug Administration (FDA) has approved andexanet alfa (Andexxa) as an antidote for the reversal of life-threatening or uncontrolled bleeding in patients treated with anticoagulants rivaroxaban and apixaban, Portola Pharmaceuticals Inc. announced.